Drugs / Zifibancimig
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04567303 | Oct 2020 → Aug 2026 | macular degeneration | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zifibancimig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04567303 ↗ |
| Known as | RO-7250284 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095379 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5095379 ↗ |
| Route | Intravitreal | “administered in multiple ascending dose levels through IVT injections” NCT04567303 ↗ |